跳至主要内容
临床试验/NL-OMON53449
NL-OMON53449招募中不适用

Integration of Whole-Genome Sequencing profiles and Immune Status in cancer - a molecular profiling protocol to broaden the view on drug targets and immune contexture in patients with melanoma and pancreatic cancer - SONATA

Amsterdam UMC0 个研究点目标入组 180 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. Diagnosis of locally advanced or metastatic cutaneous/mucosal melanoma or
  • pancreatic cancer, meeting the following characteristics:
  • a. Melanoma
  • i. Patients with histologically proven locally advanced or metastatic melanoma
  • (stage IV), with intrinsic or acquired resistance to treatment with immune
  • checkpoint inhibition (anti-PD1 antibody +/- ipilimumab)
  • ii. Patients with locoregional or distant recurrence either during, or within 3
  • months after completion or discontinuation of (neo)adjuvant anti-PD1-based
  • immunotherapy for stage III melanoma.
  • b. Pancreatic cancer
  • i. Patients with histologically proven metastatic pancreatic cancer with
  • progression under or after standard first-line chemotherapy (FOLFIRINOX or
  • gemcitabine/nab-paclitaxel).
  • 2. Patients must be willing and able to provide written informed consent and be
  • willing and able to comply with the study protocol.
  • 3. Patients must be >=18 years of age.
  • 4. Metastatic or locoregional lesion of which a tumour needle biopsy can be
  • safely obtained according to routine clinical practice.

排除标准

  • Patients with metastatic or locally advanced lesions which are not considered
  • to be technically and/or safely biopsied

研究者

发起方
Amsterdam UMC

相似试验

Integration of Whole-Genome Sequencing profiles and... | 临床试验